Tobi Related Published Studies
Well-designed clinical trials related to Tobi (Tobramycin Inhalation)
Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. [2011.04]
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. [2011.01]
Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. [2011.01]
The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease. [2010.05]
Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor. [2008.09]
A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients. [2008.07]
Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. [2007.04]
Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis. [2007.04]
Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. [2007.02]
Clinical Pharmacology Study of Bramitob((R)), a Tobramycin Solution for Nebulization, in Comparison with Tobi((R)). [2007]
A Formulation of Aerosolized Tobramycin (Bramitob((R))) in the Treatment of Patients with Cystic Fibrosis and Pseudomonas aeruginosa Infection : A Double-Blind, Placebo-Controlled, Multicenter Study. [2007]
Efficacy, Safety, and Local Pharmacokinetics of Highly Concentrated Nebulized Tobramycin in Patients with Cystic Fibrosis Colonized with Pseudomonas aeruginosa. [2007]
Well-designed clinical trials possibly related to Tobi (Tobramycin Inhalation)
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. [2011.09]
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. [2010.04]
Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. [2010.03]
Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. [2008.11.01]
Folic acid supplementation inhibits recurrence of colorectal adenomas: A randomized chemoprevention trial. [2008.07.28]
Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics. [2007.09]
Use of double-blind placebo-controlled N-of-1 trials among stimulant-treated youths in The Netherlands: a descriptive study. [2007.01]
Other research related to Tobi (Tobramycin Inhalation)
[Effect of Inhalation of Tobramycin for 12 Months on Reduction of Hospitalisation
Rate in Severe COPD]. [Article in German] [2013]
Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An
instrumental variables analysis. [2013]
Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution
300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers
in cystic fibrosis patients. [2013]
Tobramycin for the treatment of bacterial pneumonia in children. [2012]
Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with
pseudomonas airway infection. [2012]
Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients with Pseudomonas Airway Infection. [2011.11.17]
Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin. [2011.03]
Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis. [2011.02]
Adherence with tobramycin inhaled solution and health care utilization. [2011.01.20]
Economic impact of tobramycin in patients with cystic fibrosis in a managed care population. [2011]
Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in
healthy and cystic fibrosis subjects. [2011]
Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. [2010.11.15]
Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. [2010.10.20]
Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. [2010.09.29]
Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. [2010]
The use of high resolution computerized tomography (HRCT) of the chest in
evaluating the effect of tobramycin solution for inhalation in cystic fibrosis
lung disease. [2010]
Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. [2009.12]
Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. [2009.10]
Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. [2009.10]
Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. [2009.09]
Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. [2009.07.16]
Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. [2009.05]
Inhalation with Tobramycin to improve healing of tracheobronchial reconstruction. [2009.05]
Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties. [2009.04]
Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions. [2009.02]
Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. [2009.01.05]
Pulmonary deposition of inhaled tobramycin prior to and after respiratory therapy and use of inhaled albuterol in cystic fibrosis patients colonized with Pseudomonas aeruginosa. [2009.01]
Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project. [2008.08]
Elevated serum tobramycin concentrations after treatment with tobramycin inhalation in a preterm infant. [2008.07]
Development and validation of HPLC method for the determination of tobramycin in urine samples post-inhalation using pre-column derivatisation with fluorescein isothiocyanate. [2008.06.15]
Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. [2008.02]
Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland. [2008]
Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods. [2007.11]
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. [2007.07]
Other possibly related research studies
Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients. [2009.09]
Octreotide uptake in intracranial metastasis of pancreatic ductal adenocarcinoma origin in a patient with a prolonged clinical course. [2009.01]
Antiretroviral treatment and the health workforce in South Africa: how have ART workers been affected by scaling up? [2008.12]
Cellular effects of long wavelength UV light (UVA) in mammalian cells. [2008.08]
Use of antipsychotic drugs among Dutch youths between 1997 and 2005. [2008.05]
Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. [2008]
Studying co-medication patterns: the impact of definitions. [2007.04]
Cutaneous allergy testing in patients suspected of an allergic reaction to eye medication. [2009]
Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. [2009.06]
Aerosol antibiotics in cystic fibrosis. [2009.05]
Implementation of European standards of care for cystic fibrosis--control and treatment of infection. [2009.05]
Shifting patterns of inhaled antibiotic use in cystic fibrosis. [2008.09]
Aminoglycoside-induced vestibular injury: maintaining a sense of balance. [2008.09]
Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. [2008.03]
The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times. [2007.09]
Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. [2007.08]
Use of aerosolized aminoglycosides in the treatment of Gram-negative ventilator-associated pneumonia. [2007.06]
The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. [2007.07]
Day care at green care farms: a novel way to stimulate dietary intake of community-dwelling older people with dementia? [2010]
Inhaled anti-infective agents: emphasis on colistin. [2010.04]
Co-morbidity and patterns of care in stimulant-treated children with ADHD in the Netherlands. [2010.02]
DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific. [2009.11.01]
Current issues around the pharmacotherapy of ADHD in children and adults. [2009.10]
Aztreonam lysine for inhalation solution: in cystic fibrosis. [2010.10.01]
Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. [2009.12.07]
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. [2009.10.07]
Emerging treatments in cystic fibrosis. [2009.10.01]
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. [2009.09]
Development of the first inhaled antibiotic for the treatment of cystic fibrosis. [2010.12.22]
DNA methylation of IGF2, GNASAS, INSIGF and LEP and being born small for gestational age. [2011.02]
External quality assessment for the determination of diphtheria antitoxin in human serum. [2010.08]
Day care at green care farms: a novel way to stimulate dietary intake of community-dwelling older people with dementia? [2010.05]
The impact of ART scale upon health workers: evidence from two South African districts. [2010]
Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. [2011.04.04]
Inhaled antibiotics for long-term therapy in cystic fibrosis. [2011.03.16]
Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections. [2011.03]
Improving evidence-based care in cystic fibrosis through quality improvement. [2010.10]
In vitro inhibition of neutrophil elastase activity by inhaled anti-Pseudomonas antibiotics used in cystic fibrosis patients. [2010]
Inhaled anti-infective agents: emphasis on colistin. [2010]
Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients
with cystic fibrosis: a randomised multicentre study comparing two different
protocols. [2012]
Therapeutic approaches to chronic cystic fibrosis respiratory infections with
available, emerging aerosolized antibiotics. [2011]
Inhaled antibiotics for long-term therapy in cystic fibrosis. [2011]
Inhaled versus systemic antibiotics and airway inflammation in children with
cystic fibrosis and Pseudomonas. [2010]
Treatment of early Pseudomonas aeruginosa infection in patients with cystic
fibrosis: the ELITE trial. [2010]
The effects of dexamethasone and metoclopramide on early and late postoperative
nausea and vomiting in women undergoing myomectomy under spinal anaesthesia. [2014]
The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas
aeruginosa in patients with cystic fibrosis. [2014]
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with
cystic fibrosis. [2014]
Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic
review. [2014]
|